There is a number on every skincare label that tells you very little about whether the product works: the price. And there is a number that is never on the label but tells you almost everything about whether it works: the concentration of the active ingredient.
These two numbers have an uncomfortable relationship in the skincare industry. Price and active concentration do not correlate the way most consumers assume they do. Some of the most expensive serums on the Singapore market contain flagship actives at concentrations below what clinical research used to demonstrate efficacy. Some of the most aggressively marketed brightening and anti-ageing products list their hero ingredient in the seventh position on the INCI list, after water, butylene glycol, and three different emollients.
This article explains how AURA’s formulas are positioned on concentration and value — specifically why we made the choices we made on active load, what those choices cost us to produce, and why we are convinced it is the only approach worth taking.
The formulation economics most brands do not talk about
Skincare formulas have two cost components: the base formulation and the actives. Base formulation — water, emulsifiers, humectants, stabilisers, preservatives, texture agents — is relatively inexpensive. The cost of a skincare formula is almost entirely determined by the type and concentration of its active ingredients.
Palmitoyl Tripeptide-1 is not cheap. Copper Tripeptide-1 (GHK-Cu) is more expensive still. Acetyl Hexapeptide-8 (Argireline) is a proprietary ingredient manufactured by Lipotec that is licensed rather than freely sourced, adding a cost premium that commodity niacinamide or hyaluronic acid does not carry. Hexylresorcinol at effective brightening concentrations adds meaningful cost per unit. These are the ingredients in AURA LIFT and AURA Bright that produce the results the formulas are designed to produce. They are also the ingredients that most brands reduce first when optimising margin.
The standard industry approach to managing this cost pressure is a technique sometimes called “pixie-dusting”: including a premium active on the ingredient list at a concentration too low to produce any biological activity, but at a concentration high enough that the marketing team can feature it prominently. The ingredient is present. The INCI list is accurate. The clinical research supporting that ingredient’s efficacy was conducted at a concentration ten times higher than what is in the formula. The product is technically not making a false claim. It is simply not doing what the research suggests it should.
This is not a fringe practice. It is routine across the skincare industry at every price point, and it is how a product can command a premium price while the cost-of-goods on the formula is substantially lower than the price suggests.
What clinically active concentration actually means
Every active ingredient in AURA’s formulas has a concentration range at which clinical research demonstrates measurable biological activity. Below this range, the ingredient is present but not doing what the research says it does. At or above this range, the mechanism operates and produces the results the clinical trials measured.
For signal peptides like Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7, the effective concentration for measurable collagen stimulation in controlled studies is in the range of 3 to 10 parts per million. A formula listing these peptides in the bottom third of a 28-ingredient list is almost certainly below this threshold. The peptide is present. The fibroblasts are not receiving a signal that changes their collagen output.
For niacinamide, the clinical effective range for melanin transfer inhibition and barrier support is 2 to 5%. The clinical trials that demonstrated sebum regulation used concentrations in this range. At 0.5%, the ingredient is present but the concentration gradient required to drive it through the barrier to the layers where it acts is insufficient for the mechanism to operate at clinically meaningful intensity.
For hexylresorcinol, the 0.5% concentration used in the comparative study against 2% hydroquinone — which showed comparable brightening improvement — is the reference point. A formula listing hexylresorcinol in the final five ingredients of a long list is not at 0.5%. It is at a trace concentration that may not reach the tyrosinase it needs to inhibit at a level that changes melanin output.
AURA’s formulas position each active within or approaching its clinically effective range. This is not the same as being at the highest concentration possible — concentration above the effective range does not improve results and for some ingredients (niacinamide above 10%) can produce adverse reactions that worsen the condition being treated. The goal is effective concentration, not maximum concentration. That precision requires understanding the research rather than simply adding more.
The price comparison: what you are actually paying per active across the market
The useful comparison when evaluating skincare value is not price per millilitre. It is cost per unit of clinical-grade active delivered to the skin. A product at $280 for 30ml containing Copper Tripeptide-1 at a trace concentration is more expensive per unit of active than a product at $72 for 30ml containing Copper Tripeptide-1 at a clinically meaningful concentration. The label shows the same ingredient. The formula is not delivering the same thing.
The formulas that deliver comparable active loads to AURA LIFT — Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Acetyl Hexapeptide-8, Copper Tripeptide-1 at concentrations within or near clinical effective ranges — sit at $180 to $300+ in the Singapore market. This is the price bracket where the prestige anti-ageing serum market operates: Estée Lauder Advanced Night Repair at approximately $115 to $185 for 30ml to 50ml, SkinCeuticals C E Ferulic at $260 to $290 for 30ml, La Mer The Lifting and Firming Mask at comparable price points. These products carry significant non-formula cost components — brand equity, retail infrastructure, global advertising, luxury packaging — in addition to their formula cost.
AURA LIFT at $72 delivers its active load without those non-formula cost components. The formula cost as a proportion of the retail price is higher than in prestige brand positioning because the retail infrastructure and brand investment that absorbs a large share of prestige brand pricing does not exist in AURA’s cost structure. What you are paying for is a higher proportion than the prestige market standard.
Why we do not reduce concentration to compete on price
There is a version of AURA that could be sold for $40. We could reduce the Copper Tripeptide-1 to trace concentration, use a commodity niacinamide at 0.3%, substitute a non-palmitoylated peptide for the delivery-engineered actives, and reduce the ceramide content to a label-compliant minimum. The ingredient list would look similar. The mechanism would not be.
We have not done this for one reason: it would not produce the results we want our customers to experience. The reason AURA exists is to give Singapore skin access to clinical-grade active formulation at a price that is not predicated on global brand infrastructure. If we achieve that price by reducing the active load to the point where the formula is no longer clinical-grade in practice, we have not achieved anything. We have created another product that lists premium actives on the label and does not deliver them to the skin at the concentration that matters.
This commitment has had a real cost in 2026. Supply chain pressures this year increased the cost of several key actives, including the palmitoylated peptides and GHK-Cu that are central to AURA LIFT’s formula. The commercial response to this kind of input cost increase in a margin-managed product is to quietly reduce concentration in the next manufacturing batch — the product looks the same, the label is the same, the marketing continues unchanged, and the formula is not the same as the one the customer previously purchased and re-purchased.
We absorbed the cost increase. The active concentrations in the current AURA LIFT batch are the same as the preceding one. This is not a heroic decision. It is the minimum standard required for the product to remain what it claims to be. But it is worth stating clearly, because it is not the decision every brand makes when the same pressure arrives.
The sensory experience trade-off
High-active-concentration formulas and premium sensory experience are not incompatible, but they are in tension. A serum optimised for active delivery — palmitoylated peptides in a lightweight aqueous vehicle, stabilised for tropical ambient temperatures, absorbing in 60 seconds without residue — feels functional rather than luxurious. It does not have the silky dry-down of a silicone-forward formula. It does not have the subtle signature scent of a prestige product. It does not feel dramatically different on the skin in the first 30 seconds of application.
Many brands optimise toward the sensory experience precisely because it is the experience that drives immediate repurchase. A serum that feels beautiful at application generates the daily positive sensory feedback that motivates consistent use regardless of whether structural results are accumulating. A serum that absorbs cleanly in 60 seconds and then does nothing perceptible on the surface requires the user to maintain eight to twelve weeks of consistent use before the result is visible enough to motivate continued repurchase from the evidence of what the skin actually looks like rather than from how the product feels.
We have chosen the second approach. Not because sensory experience does not matter — it does, and we pay attention to texture, absorption, and skin feel in our formulation process — but because a formula optimised for sensory performance at the expense of active density is not producing what we want to produce for our customers. The experience we want AURA to deliver is in the mirror at week ten, not in the fingertips at application. Both can be real. When forced to prioritise, we prioritise the mirror.
How to evaluate this yourself
If you want to assess the active concentration of any skincare product, including AURA’s, apply three checks:
Position on the INCI list. Ingredients are listed in descending order of concentration. A peptide in position 22 of a 25-ingredient list is at a trace concentration. A peptide in position 5 or 6 is at a meaningful concentration. Position alone does not give you the exact percentage, but it tells you whether the active is a significant part of the formula or a marketing addition.
Presence of a delivery system. For peptides, check for palmitoylation (the ingredient name starts with “Palmitoyl”). For vitamin C, check for a stable derivative appropriate to the product’s pH rather than L-ascorbic acid in a formula with ingredients that would raise the pH. For AHAs, check the pH of the formula (below 3.5 is required for effective exfoliation at cosmetic concentrations). A clinical-grade active without a delivery system appropriate to its chemistry is not reaching the skin layer where it needs to act.
The published full INCI. AURA publishes the full ingredient list for both formulas. View it at go-aura.co/products/pl-aura-lifter-serum for AURA LIFT and go-aura.co/products/aura-bright-pigmentation-and-uneven-skin-tone for AURA Bright. Check the position of each active. Check for palmitoylation on the peptides. Cross-reference the actives against the published clinical research at the concentrations listed. Then do the same for the product you are currently using or considering switching from. The comparison is informative.
The price of a skincare product tells you about the brand. The active concentration tells you about the formula.
AURA is priced to reflect the formula. The formula is concentrated to reflect the clinical research. The clinical research determines what the skin actually needs. That chain — research to formula to price to result — is the logic behind every formulation decision we make.
0 comments